Nautilus Biotechnology Reports $190,000 Revenue in Q2 2026, Faces $14.5 Million Net Loss

Nautilus Biotechnology, Inc. reported its financial results for the second quarter of 2026, revealing total revenue of $190,000, a significant increase from zero revenue in the same period last year. This revenue was primarily driven by $180,000 in grant revenue from The Michael J. Fox Foundation and $10,000 in service revenue from its Early Access Program. Despite this revenue generation, the company continues to face substantial operating losses, with a net loss of $14.5 million for the quarter, a slight improvement from a net loss of $15.0 million in the prior year.

For the first half of 2026, Nautilus recorded a total revenue of $190,000, again reflecting the commencement of grant activities and service revenue. The company’s operating expenses decreased to $32.1 million from $35.9 million in the same period last year, primarily due to reductions in research and development costs, which fell by 12% to $19.3 million. Selling, general, and administrative expenses also decreased by 9% to $12.7 million, attributed to lower stock-based compensation and personnel costs.

In terms of operational developments, Nautilus has initiated its Early Access Program, allowing select customers to access its proteomics platform for targeted applications. The company is focusing on expanding its offerings, including assays for specific proteins associated with diseases such as Alzheimer’s and cancer. As of June 30, 2026, Nautilus had cash, cash equivalents, and short-term investments totaling $84 million, which management believes will be sufficient to fund operations for at least the next twelve months.

The company’s accumulated deficit has reached $361.2 million, reflecting ongoing investments in research and development since its inception. Nautilus has indicated that it will require additional funding to support its commercialization efforts and ongoing operational costs. The company plans to pursue various financing options, including equity and debt offerings, to secure the necessary capital for future growth.

Looking ahead, Nautilus aims to initiate its commercial launch in early 2027, with plans to offer its Nautilus Voyager platform for pre-orders and begin instrument shipments mid-year. The company is also working on enhancing its sales and marketing capabilities to support this launch. However, Nautilus acknowledges the potential impact of global economic conditions and market volatility on its ability to raise funds and execute its business strategy effectively.